Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR)’s stock price has decreased by -0.57 compared to its previous closing price of 21.08. However, the company has seen a 12.87% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-19 that Arrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with a phase 3 trial plan in homozygous familiar hypercholesterolemia patients. We could see as many as three phase 1/2 readouts this year from programs that were recently partnered with Sarepta, and ARO-DM1 program milestones point to registrational intent.
Is It Worth Investing in Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Right Now?
The 36-month beta value for ARWR is also noteworthy at 0.92. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for ARWR is 116.94M, and at present, short sellers hold a 8.60% of that float. The average trading volume of ARWR on February 21, 2025 was 2.06M shares.
ARWR’s Market Performance
ARWR’s stock has seen a 12.87% increase for the week, with a 6.07% rise in the past month and a 12.87% gain in the past quarter. The volatility ratio for the week is 4.77%, and the volatility levels for the past 30 days are at 5.36% for Arrowhead Pharmaceuticals Inc The simple moving average for the last 20 days is 4.55% for ARWR stock, with a simple moving average of -6.77% for the last 200 days.
Analysts’ Opinion of ARWR
Many brokerage firms have already submitted their reports for ARWR stocks, with Goldman repeating the rating for ARWR by listing it as a “Neutral.” The predicted price for ARWR in the upcoming period, according to Goldman is $31 based on the research report published on June 05, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see ARWR reach a price target of $29. The rating they have provided for ARWR stocks is “Buy” according to the report published on December 04th, 2023.
Citigroup gave a rating of “Neutral” to ARWR, setting the target price at $33 in the report published on September 19th of the previous year.
ARWR Trading at 3.92% from the 50-Day Moving Average
After a stumble in the market that brought ARWR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.92% of loss for the given period.
Volatility was left at 5.36%, however, over the last 30 days, the volatility rate increased by 4.77%, as shares surge +6.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.01% lower at present.
During the last 5 trading sessions, ARWR rose by +12.87%, which changed the moving average for the period of 200-days by -13.14% in comparison to the 20-day moving average, which settled at $20.05. In addition, Arrowhead Pharmaceuticals Inc saw 11.49% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARWR starting from OLUKOTUN ADEOYE Y, who sale 959 shares at the price of $21.00 back on Jan 23 ’25. After this action, OLUKOTUN ADEOYE Y now owns 35,781 shares of Arrowhead Pharmaceuticals Inc, valued at $20,139 using the latest closing price.
OLUKOTUN ADEOYE Y, the Director of Arrowhead Pharmaceuticals Inc, proposed sale 959 shares at $20.97 during a trade that took place back on Jan 23 ’25, which means that OLUKOTUN ADEOYE Y is holding shares at $20,108 based on the most recent closing price.
Stock Fundamentals for ARWR
Current profitability levels for the company are sitting at:
- -250.38 for the present operating margin
- -2.72 for the gross margin
The net margin for Arrowhead Pharmaceuticals Inc stands at -255.89. The total capital return value is set at -0.68. Equity return is now at value -600.68, with -78.01 for asset returns.
Based on Arrowhead Pharmaceuticals Inc (ARWR), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -4.24. The debt to equity ratio resting at 2.2. The interest coverage ratio of the stock is -12.87.
Currently, EBITDA for the company is -561.51 million with net debt to EBITDA at -0.11. When we switch over and look at the enterprise to sales, we see a ratio of 1081.99. The receivables turnover for the company is 1.0for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.09.
Conclusion
In summary, Arrowhead Pharmaceuticals Inc (ARWR) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
